Products
Solid Tumors
Pan-Cancer
Cancer Type-Specific
Minimal Residual Disease
Hematologic Malignancies
Pan-Cancer
Cancer Type-Specific
Cancer Early Detection
Hereditary Cancers
Services
Central Lab Testing
Local Testing Solutions
IVD Kit Solutions
RUO Kit Solutions
Research Services
DNA Sequencing
RNA Sequencing
Technology
Our Technology
Publications
Partnerships
About Us
What is Precision Oncology?
Our Company
Our Team
Certificates & Accreditation
News
Newsroom
Geneseeq Blogs
Join Us
Contact Us
Search
August 11, 2026
Geneseeq Expands PanTRKare™ with a Third NMPA-Approved CDx Application for VELMARTO® (Eratrectinib)
by GENESEEQ
November 10, 2025
Geneseeq Receives NMPA Approval for PanTRKare™ – China’s First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions
by GENESEEQ
December 3, 2024
GENESEEQ’S NGS LIQUID BIOPSY KIT MARKS THE FIRST TO ENTER NMPA’S SPECIAL REVIEW AND APPROVAL OF INNOVATIVE MEDICAL DEVICE
by GENESEEQ
October 13, 2023
GENESEEQ RECEIVES CHINESE NMPA APPROVAL FOR LUNG CANCER TUMOR MUTATIONAL BURDEN NGS TEST KIT
by Geneseeq
Privacy Preference Center
Privacy Preferences
×
